Company Description
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.
The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.
The company’s pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel for the treatment of cystic fibrosis.
The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007.
The company was incorporated in 2001 and is headquartered in Austin, Texas.
| Country | United States |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | James Windsor |
Contact Details
Address: 12407 N. Mopac Expy., Suite 250 #390 Austin, Texas 78758 United States | |
| Phone | 737 802 1989 |
| Website | reintx.com |
Stock Details
| Ticker Symbol | RNTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001420565 |
| CUSIP Number | 00887A204 |
| ISIN Number | US00887A2042 |
| Employer ID | 13-4196017 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James Brian Windsor Ph.D. | Chief Executive Officer, President and Director |
| Dr. Cory M. Hogaboam Ph.D. | Chief Scientific Officer |
| Jennifer Faigle | Counsel |
| Ron Chen | Vice President of Finance and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 9, 2025 | 8-K | Current Report |
| Sep 5, 2025 | EFFECT | Notice of Effectiveness |
| Sep 3, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 19, 2025 | 8-K | Current Report |
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Jul 30, 2025 | 8-K | Current Report |
| Jul 30, 2025 | 424B5 | Filing |
| Jul 30, 2025 | 424B5 | Filing |
| Jul 23, 2025 | 8-K | Current Report |
| Jul 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |